Z
Zandra E. Walton
Researcher at University of Pennsylvania
Publications - 24
Citations - 4585
Zandra E. Walton is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 18, co-authored 23 publications receiving 3819 citations. Previous affiliations of Zandra E. Walton include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
MYC, Metabolism, and Cancer
TL;DR: Because of the reliance of MYC-driven cancers on specific metabolic pathways, synthetic lethal interactions between MYC overexpression and specific enzyme inhibitors provide novel cancer therapeutic opportunities.
Journal ArticleDOI
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Zhao Chen,Katherine A. Cheng,Zandra E. Walton,Yuchuan Wang,Hiromichi Ebi,Takeshi Shimamura,Yan Liu,Tanya Tupper,Jing Ouyang,Jie Li,Peng Gao,Michele S. Woo,Chunxiao Xu,Masahiko Yanagita,Abigail Altabef,Shumei Wang,Charles Lee,Yuji Nakada,Christopher G. Peña,Yanping Sun,Yoko Franchetti,Catherine Yao,Amy Saur,Michael D. Cameron,Mizuki Nishino,D. Neil Hayes,Matthew D. Wilkerson,Patrick J. Roberts,Carrie B. Lee,Nabeel Bardeesy,Mohit Butaney,Lucian R. Chirieac,Daniel B. Costa,David M. Jackman,Norman E. Sharpless,Diego H. Castrillon,George D. Demetri,Pasi A. Jänne,Pier Paolo Pandolfi,Lewis C. Cantley,Andrew L. Kung,Jeffrey A. Engelman,Kwok-Kin Wong +42 more
TL;DR: It is demonstrated that concomitant loss of either p53 or Lkb1, two clinically relevant tumour suppressors, markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy, highlighting the rationale for synchronous co-clinical trials.
Journal ArticleDOI
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Bo Li,Bo Qiu,David Lee,David Lee,Zandra E. Walton,Joshua D. Ochocki,Lijoy K. Mathew,Lijoy K. Mathew,Anthony A. Mancuso,Terence P. Gade,Brian Keith,Itzhak Nissim,Itzhak Nissim,M. Celeste Simon,M. Celeste Simon +14 more
TL;DR: It is determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumours examined, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours.
Journal ArticleDOI
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu,Christine M. Fillmore,Shohei Koyama,Hongbo Wu,Yanqiu Zhao,Zhao Chen,Grit S. Herter-Sprie,Esra A. Akbay,Jeremy H. Tchaicha,Abigail Altabef,Jacob B. Reibel,Zandra E. Walton,Hongbin Ji,Hideo Watanabe,Pasi A. Jänne,Diego H. Castrillon,Anil K. Rustgi,Adam J. Bass,Gordon J. Freeman,Robert F. Padera,Glenn Dranoff,Peter S. Hammerman,Peter S. Hammerman,Carla F. Kim,Carla F. Kim,Kwok-Kin Wong +25 more
TL;DR: It is demonstrated that biallelic inactivation of Lkb1 and Pten in the mouse lung leads to SCC that recapitulates the histology, gene expression, and microenvironment found in human disease.
Journal ArticleDOI
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl,Anthony C. Faber,Danan Li,Mei-Chih Liang,Katherine Crosby,Matthew Onsum,Olga Burenkova,Emily Pace,Zandra E. Walton,Lin Nie,Aaron Fulgham,Youngchul Song,Ulrik B. Nielsen,Jeffrey A. Engelman,Kwok-Kin Wong +14 more
TL;DR: Results suggest that targeting ErbB3 with MM-121 can be an effective therapeutic strategy for cancers with ligand-dependent activation of Erb B3.